Inflammatory muscle diseases identified as being caused by community-acquired, methicillin-resistant staphylococcus aureus (MRSA) infection have been treated primarily with clindamycin and vancomycin in combination. Tetracyclines have also been found to be protective against MRSA.
Infective Pyomyositis and Myositis in Children in the Era of Community-Acquired, Methicillin-Resistant Staphylococcus aureus Infection. Clin Infect Dis (2006) 43 (8): 953-960.
Retrospective review of increasing prevalence of community-acquired, methicillin-resistant staphylococcus aureus (MRSA) infection at the Texas Children’s Hospital, in Houston, Texas, during 2000-2006. In 45 cases of previously healthy children, aged 0.06-15 years old (mean patient age of 5.5 years), presenting with bacterial pyomyositis or myositis, 57.8% were found to have staphylococcus aureus infections and just 2.2% were found to have Streptococcus pyogenes infection. The remaining 40% of children were culture negative for these infections. Empirical treatments were primarily with the antibiotics, vancomycin and clindamycin.
Note: New antibiotics and compounds to increase MRSA sensitivity to treatment are in development as reported in Science Daily and tetracyclines remain a prominent tool in the fight against this infection.